Human iPSCs-based modeling unveils chromatin remodeling induced by SETBP1 mutation as a potential initiating factor in GATA2 deficiency
Preprint
- 4 September 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Patients with GATA2 deficiency are predisposed to developing myelodysplastic syndrome (MDS), which can progress to acute myeloid leukemia (AML). This progression is often associated with the acquisition of additional cytogenetic and somatic alterations. Mutations in SETBP1 and ASXL1 genes are frequently observed in pediatric GATA2 patients, but their roles in disease progression remain poorly understood. Genome editing of induced pluripotent stem cells (iPSCs) enabled precise reconstruction of mutation combinations found in patients. Here we developed a human hiPSC-based model to study the impact of SETBP1 and ASXL1 mutations in context of GATA2 deficiency. We show that germline heterozygous GATA2 mutation alone showed no significant effect on myeloid development, while the addition of SETBP1 and ASXL1 mutations impaired myelopoiesis, resulting in monocytopenia. We identified a key role of the SETBP1 mutation in promoting chromatin remodeling near genes involved in myeloid neoplasms, which likely initiated the blockage of myeloid differentiation observed in vitro. Motif analysis of more accessible chromatin regions in the SETBP1 and SETBP1/ASXL1 mutant background highlighted an enrichment for MEIS1, PU.1, RUNX1, and HOXA9, implicating these factors in the disease progression. Our study establishes a novel humanized model system for studying GATA2 deficiency. We demonstrate that SETBP1 mutations act as a primary driver in hematopoietic impairment, providing insights that may inform future therapeutic strategies for patients progressing to MDS/AMLKeywords
All Related Versions
- Version 1, 2024-09-04, Research Square
- Published version: Nature Communications, 16 (1), 10035.
This publication has 53 references indexed in Scilit:
- LOSS OF HSC STEMNESS IDENTITY IS ASSOCIATED WITH EXHAUSTION AND HYPORESPONSIVENESS IN GATA2 DEFICIENCY SYNDROMEEJC Paediatric Oncology, 2023
- Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformationiScience, 2021
- GATA2 deficiency syndrome: A decade of discoveryHuman Mutation, 2021
- Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiencyStem Cell Research, 2021
- iPSC modeling of stage-specific leukemogenesis reveals BAALC as a key oncogene in severe congenital neutropeniaCell Stem Cell, 2021
- Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targetsCell Stem Cell, 2021
- Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML)Experimental Hematology, 2018
- Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable LeukemiaCell Stem Cell, 2017
- MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AMLCell Reports, 2016
- Discovering Hematopoietic Mechanisms through Genome-wide Analysis of GATA Factor Chromatin OccupancyMolecular Cell, 2009